AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05557409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, taken twice daily
Trial: NCT06433362
Drug: CMOEP
RxNorm normalized name: Chlormethine oxide ethyl phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 3 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1,every 3 weeks; Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 3 mg/m2, the maximum dose of 4mg),every 3 weeks; Drug: Etoposide Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3,every 3 weeks;
Trial: NCT04767542
Drug: Intravenous Infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: analgesic
Trial: NCT05500508
Drug: AMXT1501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 200 mg (free base content) enterically-coated capsules
Trial: NCT04609046
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT06093191
Drug: Tobramycin Inhalant Product
RxNorm normalized name: tobramycin Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
Trial: NCT06093191
Drug: Natural saline inhalation
RxNorm normalized name: Broncho Saline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
Trial: NCT06427980
Drug: Chinese Herbal formula HuoXue LiShui
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention consists of the oral administration of granule with either HXLS or a placebo substance, one bag (28.5 g) twice daily after meals for a period of 8 weeks. The granules are produced from four Chinese herbal pieces: Yi Mu Cao (Leonuri Herbal, 15.0g), Zhi Shui Zhi (Hirudo, 1.5g), Tao Ren (Semen persicae, 6.0g), and Hong Hua (Carthami Flos, 6.0g).
Trial: NCT06427980
Drug: Chinese Herbal formula Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be consistent with the HXLS oral granules in appearance, taste, and weight, to the greatest extent possible. In terms of outer packing, the HXLS and placebo granules will be exactly the same. It included Hu Jing (28.5g)
Trial: NCT06639256
Drug: Test Product HY07121
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HY07121 should be administered intravenously at recommended dose.
Trial: NCT06228846
Drug: YY001
RxNorm normalized name: I'm afraid I don't have enough information to determine the full generic name for the drug abbreviation 'YY001'. Drug abbreviations can vary and may not be standardized, so without more context about the specific drug or clinical trial, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04984876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection once every 4 weeks
Trial: NCT06637137
Drug: Iron
RxNorm normalized name: Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who present a state of hypoferritinemia or a state of reduced transferrin saturation will undergo administration of i.v iron at least 2 weeks before scheduled cardiac surgery, plus acid folic and B vitamin co-administration.
Trial: NCT05526144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets 25 mcg daily. Subjects in the placebo group will receive placebo tablets at a dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for a one year duration.
Trial: NCT06637371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection
Trial: NCT06639997
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching doses of placebo as an IM injection or IV bolus
Trial: NCT05239741
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m\^2 given as an IV on Day 1 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
Trial: NCT05715788
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide inhalation at 20 ppm
Trial: NCT04682106
Drug: LY3493269
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04682106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04682106
Drug: Salcaprozate Sodium
RxNorm normalized name: Salcaprozate sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05781243
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the NS (Normal Saline) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
Trial: NCT05440734
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 Mg Oral Tablet, slow release
Trial: NCT06210971
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 625mg/m\^2 or 1000mg/m\^2 bid.
Trial: NCT06084104
Drug: DZD9008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 200mg DZD9008
Trial: NCT05145569
Drug: HCW9218
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCW9218 is an immunotherapeutic comprising transforming growth factor-b (TGF-b) receptor II and interleukin (IL)-15/IL-15 receptor a domains.
Trial: NCT05818111
Drug: steroid
RxNorm normalized name: Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triamcinolone 40mg 4cc
Trial: NCT05818111
Drug: Xylocaine 2 % Injectable Solution
RxNorm normalized name: Xylocaine 2 % Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xylocaine 2% 4cc
Trial: NCT06184321
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instilled into IPC
Trial: NCT05092841
Drug: PXT3003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered PXT3003 twice daily (bid) at 10mL.
Trial: NCT05092841
Drug: PXT3003 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered PXT3003 placebo twice daily (bid) at 10mL.
Trial: NCT06484816
Drug: TGRX-1942
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At dose escalation phase, TGRX-1942 will be given orally to patient once a day under a 7-dose sequence of 4mg, 10mg, 20mg, 30mg, 40mg, 50mg, and 60mg. The dose level a particular patient will be assigned depends on the progression of the study and PI evaluation on the safety of previous dose group(s).
Trial: NCT04917029
Drug: Dexmedetmidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1: infusion of Dexmedetmidine 0.5 µg/kg/h
Trial: NCT05336721
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 on Days 1-14 in a repeating 21-day cycle
Trial: NCT04804072
Drug: Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOUD for OUD
Trial: NCT04804072
Drug: HIV treatment for participants living with HIV not already in care
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV treatment for participants living with HIV not already in care
Trial: NCT04804072
Drug: PrEP for participants without HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP for participants without HIV
Trial: NCT06418529
Drug: tumor necrosis factor inhibitors (TNFi)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New index treatment of TNFi
Trial: NCT05067517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
Trial: NCT00989807
Drug: Aztreonam lysine
RxNorm normalized name: aztreonam lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily
Trial: NCT04768569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
Trial: NCT04489160
Drug: C1 Inhibitor, Human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6000 IU C1-INH
Trial: NCT04489160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline
Trial: NCT05092802
Drug: HLX208
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450mg bid po
Trial: NCT04830397
Drug: QLS-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic solution 1x daily
Trial: NCT05028062
Drug: XR-NTX 380 mg, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of XR-NTX 380 mg, intramuscular injection.
Trial: NCT05028062
Drug: Placebo intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of XR-NTX 380 mg, intramuscular injection.
Trial: NCT06568471
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00705796
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AndroGel® 50 mg, once daily in the morning after washing/showering.
Trial: NCT05403281
Drug: DW6012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: DW6012 Single oral administration of DW6012 after an overnight fast~Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast
Trial: NCT05068102
Drug: [89Zr]Zr- BI 770371
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[89Zr\]Zr- BI 770371, specifically radiolabelled for immune-PET
Trial: NCT05212246
Drug: Placebo Vehicle Control Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
Trial: NCT06568588
Drug: S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg three times a day for 4 months
Trial: NCT05661201
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;
Trial: NCT05026177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo given b.i.d. for 76 weeks
Trial: NCT06779435
Drug: Conventional immunochemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference options for a combined regimen include CR-CHOP, C-Pola-R-CHP, etc.~Subjects whose efficacy is assessed as CR after the end of induction therapy will enter consolidation therapy. Tucidinostat maintenance therapy or autologous hematopoietic stem cell transplantation may be an option. Tucidinostat maintenance therapy will be performed every 3 weeks. Single-drug maintenance is recommended to last 24 weeks
Trial: NCT04406857
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05113251
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered by intravenous infusion
Trial: NCT05113251
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered by intravenous infusion
Trial: NCT03673735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (one dose) before CRT and for 6 months Q4W after CRT
Trial: NCT05244980
Drug: TDM-105795
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDM-105795 topical solution
Trial: NCT05244980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for TDM-105795 topical solution
Trial: NCT05799378
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine-matching placebo capsule. Administered orally.
Trial: NCT05597878
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given after surgery 1000 mg by mouth 4 times daily (every 6 hours)
Trial: NCT05597878
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given during surgery 15 mg or 30 mg intravenously 3 times daily (every 8 hours). After surgery 15 mg IV three times daily (every 8 hours).
Trial: NCT05597878
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given during surgery 1 mg intravenously 4 times daily (every 6 hours). After surgery 1000 mg by mouth four times daily (every 6 hours)
Trial: NCT05884333
Drug: Conditioning Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning: Cyclophosphamide (CY) 50 mg/kg x1 (day -6), Fludarabine (FLU) 30 mg/m2 x5 (days -6 to -2), Thiotepa (THIO) 5 mg/kg x2 (days -5 \& -4), Total Body Irradiation (TBI) 200 cGy x2 (days -2 \& -1). GVHD prophylaxis: Cyclosporine (CSA) 3 mg/kg q12 hours \& Mycophenolate Mofetil (MMF) 15 mg/kg q8 hours (starting IV day -3).
Trial: NCT06219941
Drug: AZD0901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody-drug conjugate/Biologic
Trial: NCT06219941
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy agents
Trial: NCT06219941
Drug: l-leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy agents
Trial: NCT06346509
Drug: PORT-77
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy adult participants will receive a single oral dose of PORT 77.
Trial: NCT06346509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy adult participants will receive matching placebo on Day 1.
Trial: NCT05742061
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The injection will be given at a site near the superolateral pole of patella in the suprapatellar pouch under aseptic conditions and the patient will be advised to take one day of rest after injection and apply ice to the area if there are any signs of inflammation.
Trial: NCT05287113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intravenously.
Trial: NCT05222802
Drug: ERAS-801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06510764
Drug: Ziyinxiehuo Granules of traditional Chinese Medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziyinxiehuo Granules of traditional Chinese Medicine which includes shengdi 15g, xuanshen 9g, zexie 9g, zhimu9g, huangbai 9g, zhiguiban 9g, maiya 15g, tiandong 9g, zhigancao 9g,and will be administered after dissolved, 1package every time, 2 times per day after a meal.
Trial: NCT05845398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline for injection.
Trial: NCT05894694
Drug: first-line scheme+compound kushen injection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab+compound kushen injection Compound Kushen injection: intravenous infusion, 20ml at a time, diluted with 200ml sodium chloride injection, once a day, each cycle of chemotherapy should reach the cumulative dose of 200ml.
Trial: NCT05894694
Drug: palliative care group first-line scheme
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab
Trial: NCT05620823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral; Tablet
Trial: NCT06364930
Drug: Placebo 10mg Tab
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10mg Tab QD for 60 months.
Trial: NCT06478251
Drug: NW-301V
RxNorm normalized name: DRESSING,HYDRASORB 4IN X 4IN KEN#1694-NW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCR-T T cell targeting KRAS G12V mutation
Trial: NCT06478251
Drug: NW-301D
RxNorm normalized name: DRESSING,HYDRASORB 4IN X 4IN KEN#1694-NW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCR-T T cell targeting KRAS G12D mutation
Trial: NCT04924114
Drug: MK-6194
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT04924114
Drug: MK-6194-matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT06159686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The application of the placebo cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
Trial: NCT06414798
Drug: Drug: ABBV-1088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Oral Capsule
Trial: NCT06414798
Drug: Drug: Placebo for ABBV-1088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Oral Capsule
Trial: NCT05719558
Drug: ASP1002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous (IV) infusion
Trial: NCT06567769
Drug: GC1130A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICV injection
Trial: NCT05636293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06541691
Drug: Plain aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain aspirin tablet 81 mg, once daily
Trial: NCT05891496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to semaglutide will be administered once weekly subcutaneously.
Trial: NCT04533347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.
Trial: NCT05638672
Drug: Huashi Baidu Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granule is produced by Guangdong Yifang Pharmaceutical Co., Ltd. with a specification of 5g × 12 bags, twice a day, take 2 sachets each time with boiling water.
Trial: NCT05706454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered orally twice a day
Trial: NCT05564598
Drug: Anti-viral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive anti-viral therapy with one of the following:~4.2.2 Valganciclovir Dosing: 16 mg/kg/dose PO q12h OR 4.2.3 Ganciclovir Dosing: 6 mg/kg/dose IV q12h~Dose adjustments:~* Reduce dose by 50% for ANC less than 500 cells/mm3~* Hold the dose if ≤ 200 cells/mm3 until recovery ≥ 500 cells/mm3~* Treatment will continue for 6 months
Trial: NCT06310967
Drug: IG3018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06578052
Drug: Irinotecan liposome Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan liposome: intravenous infusion, day 1, every 2 weeks Capecitabine: oral, twice daily (bid), days 1 to 7, take for one week and then have a one-week interval.~Each 2-week period is considered a treatment cycle, with an expected treatment of 6 cycles. Subsequent maintenance treatment will be determined by the investigator's protocol until disease progression or intolerable toxicity occurs.
Trial: NCT04855526
Drug: High THC/High CBD Marihuana
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high THC (65 mg THC) and high CBD (50 mg CBD)
Trial: NCT04855526
Drug: No THC/No CBD Marihuana
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no THC (0 mg THC) and no CBD (0 mg CBD); placebo drug
Trial: NCT05514847
Drug: Aspirin 81Mg Ec Tab
RxNorm normalized name: ASPIRIN 81MG EC TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
Trial: NCT05514847
Drug: Aspirin 162Mg Ec Tab
RxNorm normalized name: ASPIRIN 162MG EC TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 162 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
Trial: NCT06291064
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Epirubicin.
Trial: NCT06291064
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is a pill that will be taken by mouth daily for 6 months after surgery is completed.